Avanafil - VIVUS

Drug Profile

Avanafil - VIVUS

Alternative Names: Spedra; Stendra; TA-1790; Zepeed

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tanabe Seiyaku
  • Developer Endo International; JW Pharmaceutical; Menarini; VIVUS
  • Class Erectile dysfunction therapies; Pyrimidines; Small molecules
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Erectile dysfunction

Highest Development Phases

  • Marketed Erectile dysfunction
  • Discontinued Female sexual dysfunction; Premature ejaculation

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 28 Mar 2018 Avanafil sub-licensed to Acerus Pharmaceuticals for distribution and marketing in Canada
  • 28 Mar 2018 Acerus Pharmaceuticals announces intention to submit New Drug Submission with Health Canada for Erectile dysfunction in second-half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top